Lock Cap 9 3
By: Clarín, The Times, Thursday , June 3, 2010 Another advance in the fight against cancer. Is under development. Research shows that the cancer involves irregular cells produce small amounts of proteins called "antigens"
. The test has been tried successfully in the presence of lung cancer. A blood tests help detect cancer at least five years before the tumor is formed is being developed by U.S. and British scientists and would be introduced in Britain during the first months of next year, according to The Times newspaper Sunday, June 6, 2010
, London. In the United States and was successfully tested in the presence of lung cancer. After 15 years of research at the University of Nottingham, Great Britain, and in Kansas, United States, researchers found that can accurately identify the first signs that a person's immune system will emit while the cancer begins to develop. The detection is achieved, thus, very early, before the tumor is discovered. That would combat the disease with much anticipation physical symptoms of cancer do not appear at least until this disease develops in two thirds, for example, in a case of lung cancer can be then the size of a ball tennis. The cases of lung cancer detection and pancreas are generally too late can mean certain death. diagnostic studies through CT scanners and reveal the existence of a tumor when there are 20 cell divisions, usually death comes with the 40 cell divisions. This new analysis by a blood test may be essential to prevent disease progression and originally began to be investigated and used in cases of lung cancer. In fact, in the United States start to affect the end of this month, but in Britain the authorization process is slower. The technology, developed by a company called Oncimmune, works to identify how the immune system responds to the first molecular signs of tumor development.
Research shows that the cancer involves irregular cells produce small amounts of proteins called antigens. This forces the immune system to react to produce an enormous amount of antibodies. Following this activity and identify what combination of antigens indicates the presence of a particular type of cancer, scientists might think this test, which requires only 10 ml of blood from the patient. That is the key to the operation of this new test. In Oncimmune announced that they intend to continue their development for early detection of not only lung cancer but also breast, colon, ovary and prostate. 
El profesor John Robertson, un especialista en cáncer de mama que lideró la investigación, dijo que ya hay una investigación en marcha para producir un test para este tipo de cáncer. El investigador cree que la tecnología que se está utilizando para la detección de señales de cáncer en sangre puede mejorar la detección del 90 por ciento de los tumores en los próximos años. Explicó, además, que los científicos que trabajan en esta área están viendo últimamente carcinomas de una manera que jamás vieron antes. Algo que los sorprende bastante. “Es como si el cuerpo gritara tengo cáncer antes de que pudiera ser detectado” , Robertson plotted. test presentation was made at the annual conference of the American Society of Oncology in Chicago next week, a meeting that is a classic for oncologists in the world. More details will be announced at that meeting, but is known to have been tested on 8,000 people in Britain and the United States.
El profesor John Robertson, un especialista en cáncer de mama que lideró la investigación, dijo que ya hay una investigación en marcha para producir un test para este tipo de cáncer. El investigador cree que la tecnología que se está utilizando para la detección de señales de cáncer en sangre puede mejorar la detección del 90 por ciento de los tumores en los próximos años. Explicó, además, que los científicos que trabajan en esta área están viendo últimamente carcinomas de una manera que jamás vieron antes. Algo que los sorprende bastante. “Es como si el cuerpo gritara tengo cáncer antes de que pudiera ser detectado” , Robertson plotted. test presentation was made at the annual conference of the American Society of Oncology in Chicago next week, a meeting that is a classic for oncologists in the world. More details will be announced at that meeting, but is known to have been tested on 8,000 people in Britain and the United States.
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment